REVIVE Blend Benefits: What the Research Behind Each of Its Four Peptides Shows

Read the last two rows first. "REVIVE benefits" is shorthand for four separate literatures, and the outcomes people most want from it are the ones nobody has measured.

Two components are repair peptides and two are growth hormone secretagogues. The rationale prescribers give is that recovery has two halves: a local half, in which damaged tissue needs cells to migrate in, new vessels and new collagen, which TB-500 and GHK-Cu are described as acting on; and a systemic half, the growth hormone pulse that accompanies early deep sleep, which CJC-1295 and ipamorelin are dosed at bedtime to add to. That is a rationale, not a finding.

The proportions matter. By mass REVIVE is mostly a GHK-Cu preparation, 50 of the 70 mg in the vial. The secretagogues are in the same two-to-one ratio, and the same amounts per dose, as the standalone CJC-1295 / Ipamorelin vial. TB-500 is the smallest component, 0.1 mg per dose, much less than a standalone TB-500 prescription delivers.

What was studied. A 2006 study in the Journal of Clinical Endocrinology and Metabolism gave healthy adults single and repeated doses of CJC-1295 with DAC and reported dose-dependent rises in growth hormone lasting days. A second 2006 paper in the same journal sampled blood every ten minutes and reported that the pituitary's pulsatile pattern was preserved during stimulation: more hormone per pulse rather than a flat elevation. For ipamorelin, a 1999 study in Pharmaceutical Research modelled the response to intravenous ipamorelin in healthy male volunteers and reported a single episode of growth hormone release peaking at about forty minutes and returning to baseline.

Why two signals. CJC-1295 acts at the GHRH receptor and ipamorelin at the growth hormone secretagogue receptor, the receptor ghrelin uses: two receptors on the same pituitary cells converging on one pulse.

The limits. The CJC-1295 trials used the DAC form, which carries an albumin-binding tag and circulates for about a week. REVIVE contains CJC-1295 without DAC, which lasts roughly half an hour. What carries over is how the pituitary responds to GHRH stimulation, not the duration. The ipamorelin data were intravenous, not subcutaneous. None of these studies measured sleep, recovery, tissue repair or body composition. The difference between the two CJC-1295 forms is in CJC-1295 with DAC vs without DAC.

Evidence type. Human, small, pharmacological.

What was studied. The same 2006 healthy-adult study reported IGF-1, the hormone the liver makes in response to growth hormone, rising for more than a week after CJC-1295 with DAC, described as well tolerated.

What it means for REVIVE. IGF-1 is the measurable marker that the secretagogue half is reaching the pituitary. It is a measurement, not a benefit in itself, and the long-lasting rise belongs to the DAC form.

Evidence type. Human, small.

What was studied. Ipamorelin was described in the European Journal of Endocrinology in 1998 as "the first selective growth hormone secretagogue." In pigs, the older secretagogues GHRP-6 and GHRP-2 released growth hormone but also raised ACTH and cortisol, whereas ipamorelin released growth hormone at comparable potency without raising either.

The limit. That selectivity was shown in animals. It is the reason prescribers choose ipamorelin over older secretagogues, not a human outcome. Ipamorelin benefits covers it in depth.

Evidence type. Animal.

What the research describes. A 2005 review in Trends in Molecular Medicine describes thymosin beta-4's primary function as binding actin monomers, the protein that gives a cell its shape and lets it move, with cell migration into a wound as the described consequence. A 2012 review in Expert Opinion on Biological Therapy covers described effects on angiogenesis, inflammatory mediators and laminin-5. A July 2026 paper in Joint Diseases and Related Surgery put BPC-157, TB-500 and the combination in one experiment in 32 rats with a repaired Achilles tendon: TB-500 reached statistical significance on load-to-failure and histology.

The limits. Most of the literature concerns the full-length thymosin beta-4 protein. TB-500, the fragment, is assumed to share the actin-binding mechanism; the direct evidence for the fragment itself is much thinner. No study has looked at the 0.1 mg per dose that REVIVE delivers. There are no randomised human trials of TB-500 for injury. For a single soft-tissue injury, the BPC-157 + TB-500 stack or TB-500 alone delivers far more TB-500 per dose. More in TB-500 benefits.

Evidence type. Animal and cell.

What the research describes. A 1999 paper in the Journal of Investigative Dermatology reported faster wound closure and increased cell migration with thymosin beta-4 in rats and in cultured human cells. A 1994 study in Wound Repair and Regeneration reported improved closure of diabetic ulcers with a topical GHK-Cu gel.

The human data. Full-length thymosin beta-4 has been given to people: a 2010 study reported intravenous dosing well tolerated in healthy volunteers, and a 2012 paper reported phase 2 results in chronic pressure and venous stasis ulcers. Those used the whole protein, not the TB-500 fragment, and the GHK-Cu study was a gel applied to the wound.

Evidence type. Animal, plus human data for related molecules and routes. None of it is for the injected blend.

What the research describes. A 1988 paper in FEBS Letters reported that GHK-Cu stimulated collagen synthesis in cultured human fibroblasts, and a 1993 Journal of Clinical Investigation paper reported more connective tissue in rat wound chambers treated with it. Reviews in BioMed Research International (2015) and the International Journal of Molecular Sciences (2018) describe increased synthesis of collagen, elastin and glycosaminoglycans, a shift in the balance between the enzymes that break tissue down and their inhibitors, and antioxidant and anti-inflammatory activity. Collagen cross-linking and elastin formation are copper-dependent.

The human data. Small studies of topical GHK-Cu creams on facial skin, reporting changes in firmness, fine lines and elasticity. None used the injectable form.

Evidence type. Cell, animal, and human topical. No study has shown injected GHK-Cu does what the creams were reported to do. See GHK-Cu benefits and GHK-Cu topical vs injection.

These are the uses the secretagogue half is actually prescribed for, and there are no trials of CJC-1295 or ipamorelin, alone or together, measuring any of them. The case is inferred from physiology: the largest natural growth hormone pulse occurs in the first hours of sleep, and growth hormone acts on muscle, bone, connective tissue and fat through IGF-1. That inference is reasonable and is why physicians prescribe secretagogues; it is not the same as a measured outcome. Some prescribers describe patients reporting deeper sleep on bedtime secretagogue dosing; that is a clinical observation, not trial evidence. The one controlled clinical trial of ipamorelin, a 2014 randomised, placebo-controlled phase 2 trial in bowel-resection patients for postoperative ileus, did not meet its endpoints. More is in CJC-1295 / Ipamorelin benefits and peptides for sleep.

This is the benefit the blend exists to deliver, and it has the least evidence. No study has compared REVIVE with its components, and the one rat study that compared BPC-157, TB-500 and the pair found the combination did not outperform either alone. A blend is a convenience: one injection, one schedule, one refill. It is not a stronger version of its parts.

• That REVIVE does anything in people that its components do in cells and animals. The blend has never been tested.
• That a larger overnight growth hormone pulse produces a measurable recovery, sleep or body-composition change in the people typically prescribed it.
• That the short-acting CJC-1295 in the vial behaves like the DAC form in the 2006 trials, beyond the pituitary response.
• That 0.1 mg of TB-500 per dose does anything to a tendon.
• That injected GHK-Cu does for skin what topical GHK-Cu is reported to do.
• An effect size or a human timeline for any benefit above, long-term safety over years, or efficacy for any condition as an FDA-approved treatment. Neither REVIVE nor any component is approved for anything.

Where the components stand with the FDA

None of the four is currently in 503A Category 2. On 29 October 2024 the Pharmacy Compounding Advisory Committee voted 0 in favour, 12 against, with 1 abstention, on adding ipamorelin to the 503A Bulks List, evaluated for growth hormone deficiency and postoperative ileus. On 4 December 2024 it voted against the CJC-1295 family, evaluated for growth hormone deficiency. No final FDA determination has been issued for either. TB-500 and injectable GHK-Cu were among twelve peptides removed from Category 2 on 15 April 2026; on 23 July 2026 the committee voted 8 to 6, with one abstention, to recommend adding TB-500, with the final determination pending, and GHK-Cu is scheduled for the committee before the end of February 2027.

Who should not take REVIVE, or should discuss it first: anyone with Wilson's disease or another copper-metabolism disorder; anyone on another GHK-Cu product, which doubles the copper; anyone with diabetes or impaired glucose tolerance; anyone with an active or recent cancer; anyone pregnant or breastfeeding; and tested athletes, because growth hormone secretagogues and GHRH analogues are prohibited in sport. The component detail is in is GHK-Cu safe, is CJC-1295 / Ipamorelin safe and is TB-500 safe.

The per-dose figures are arithmetic from the vial's concentrations on a U-100 insulin syringe, where 25 units is 0.25 mL; the full chart is in REVIVE blend dosage, and the side effects in REVIVE blend side effects. The four are in fixed proportion, so every draw delivers the same split. Your physician sets your directions after reviewing your intake, and they are printed on the vial. The price covers medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. Vials ship refrigerated with ice packs, ready to use, with sterile syringes and alcohol prep pads, one vial per 28-day fill.

If one goal dominates, a narrower product may be the more targeted prescription:

REVIVE cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications and supplements, blood sugar, cancer history and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and side effects.

REVIVE is supplied as a vial and syringe only. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.